Solu-Cortef shortages
Health Canada is currently managing a shortage of Solu-Cortef (Hydrocortisone Injection). Pfizer is the sole supplier of Hydrocortisone Injection on the Canadian market and is currently reporting shortages for all four (4) strengths.
Products impacted
|
Solu-Cortef - 100mg |
Actual shortage due to a disruption of the manufacture of the drug with an estimated end date of August 31, 2023. View shortage report |
|
Solu-Cortef - 250mg |
Actual shortage due to a disruption of the manufacture of the drug with an estimated end date of August 31, 2023. View shortage report |
|
Solu-Cortef - 500mg |
Actual shortage due to a disruption of the manufacture of the drug with an estimated end date of December 29, 2023. View shortage report |
|
Solu-Cortef - 1g |
Actual shortage due to a disruption of the manufacture of the drug with an estimated end date of September 29, 2023. View shortage report |
Resources for pharmacy professionals
CPhA has collaborated with medSask on a resource to provide guidance for dealing with the ongoing shortage, which includes conservation strategies and information related to use in adrenal insufficiency.
The Solu-Cortef shortage was recently deemed a Tier 3 shortage. Tier 3 shortages are those that have the greatest potential impact on Canada’s drug supply and healthcare system.
Last updated: July 25, 2023